Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG

Trial Profile

A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 May 2019

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin
  • Indications Acute coronary syndromes; Coronary artery disease; Stroke; Thrombosis; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms TiCAB
  • Most Recent Events

    • 30 May 2019 The study was prematurely halted after recruitment of 1859 out of 3850 planned patients, according to results published in the European Heart Journal.
    • 30 May 2019 Results published in the European Heart Journal
    • 01 Aug 2018 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top